Elite Pharmaceuticals Inc., a health care company specializing in the pharmaceutical sector, is headquartered in Northvale, United States. The company is engaged in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products. Elite Pharmaceuticals has a diverse portfolio, including pain products currently in clinical trials and products that incorporate therapeutic agents such as cardiovascular, antidiabetic, anti-infective agents, as well as cough and cold preparations.
The company is publicly traded on the OTC Bulletin Board under the ticker symbol ELTP and has been a public entity since its initial public offering on July 23, 1998. As of the close of trading on January 5, 2026, Elite Pharmaceuticals’ stock was valued at $0.48. This price is notably below the 52-week high of $0.82, achieved on June 17, 2025, but above the 52-week low of $0.27, recorded on April 6, 2025.
In terms of financial metrics, Elite Pharmaceuticals Inc. has a market capitalization of approximately $510,385,760 USD. The company’s valuation is reflected in its price-to-earnings ratio of 37.7, indicating that the market price is significantly above its earnings. Additionally, the price-to-book ratio stands at 8.72, further suggesting that the market price is considerably higher than the book value.
The most recent public disclosure from Elite Pharmaceuticals Inc. was a Q2 2026 earnings call, which took place on November 18, 2025. The call highlighted a focus on rising revenues, although no new public disclosures have been made since then. For more detailed information about the company’s activities and offerings, interested parties can visit their website at www.elitepharma.com .
Overall, Elite Pharmaceuticals Inc. continues to operate within the competitive pharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products.
